In a pilot study that included children at high risk for type 1 diabetes, daily high - dose oral insulin, compared with placebo,
resulted in an immune response to insulin without hypoglycemia, findings that support the need for a phase 3 trial to determine whether oral insulin can prevent
islet autoimmunity and diabetes in high - risk children, according to a study in the April 21 issue of JAMA, a theme issue on child health.